Your browser doesn't support javascript.
loading
Increased glutamate and glutamine levels and their relationship to astrocytes and dopaminergic transmissions in the brains of adults with autism.
Oya, Masaki; Matsuoka, Kiwamu; Kubota, Manabu; Fujino, Junya; Tei, Shisei; Takahata, Keisuke; Tagai, Kenji; Yamamoto, Yasuharu; Shimada, Hitoshi; Seki, Chie; Itahashi, Takashi; Aoki, Yuta Y; Ohta, Haruhisa; Hashimoto, Ryu-Ichiro; Sugihara, Genichi; Obata, Takayuki; Zhang, Ming-Rong; Suhara, Tetsuya; Nakamura, Motoaki; Kato, Nobumasa; Takado, Yuhei; Takahashi, Hidehiko; Higuchi, Makoto.
  • Oya M; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Matsuoka K; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
  • Kubota M; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan. matsuoka.kiwamu@qst.go.jp.
  • Fujino J; Department of Psychiatry, Nara Medical University, Kashihara-shi, Nara, Japan. matsuoka.kiwamu@qst.go.jp.
  • Tei S; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Takahata K; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto-shi, Kyoto, Japan.
  • Tagai K; Medical Institute of Developmental Disabilities Research, Showa University, Setagaya-ku, Tokyo, Japan.
  • Yamamoto Y; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
  • Shimada H; Medical Institute of Developmental Disabilities Research, Showa University, Setagaya-ku, Tokyo, Japan.
  • Seki C; Department of Psychiatry, Graduate School of Medicine, Kyoto University, Kyoto-shi, Kyoto, Japan.
  • Itahashi T; Medical Institute of Developmental Disabilities Research, Showa University, Setagaya-ku, Tokyo, Japan.
  • Aoki YY; Institute of Applied Brain Sciences, Waseda University, Tokorozawa-shi, Saitama, Japan.
  • Ohta H; School of Human and Social Sciences, Tokyo International University, Kawagoe-shi, Saitama, Japan.
  • Hashimoto RI; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Sugihara G; Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Obata T; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Zhang MR; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Suhara T; Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Nakamura M; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Kato N; Center for Integrated Human Brain Science, Brain Research Institute, Niigata University, Niigata-shi, Niigata, Japan.
  • Takado Y; Department of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan.
  • Takahashi H; Medical Institute of Developmental Disabilities Research, Showa University, Setagaya-ku, Tokyo, Japan.
  • Higuchi M; Medical Institute of Developmental Disabilities Research, Showa University, Setagaya-ku, Tokyo, Japan.
Sci Rep ; 13(1): 11655, 2023 07 19.
Article en En | MEDLINE | ID: mdl-37468523
ABSTRACT
Increased excitatory neuronal tones have been implicated in autism, but its mechanism remains elusive. The amplified glutamate signals may arise from enhanced glutamatergic circuits, which can be affected by astrocyte activation and suppressive signaling of dopamine neurotransmission. We tested this hypothesis using magnetic resonance spectroscopy and positron emission tomography scan with 11C-SCH23390 for dopamine D1 receptors in the anterior cingulate cortex (ACC). We enrolled 18 male adults with high-functioning autism and 20 typically developed (TD) male subjects. The autism group showed elevated glutamate, glutamine, and myo-inositol (mI) levels compared with the TD group (p = 0.045, p = 0.044, p = 0.030, respectively) and a positive correlation between glutamine and mI levels in the ACC (r = 0.54, p = 0.020). In autism and TD groups, ACC D1 receptor radioligand binding was negatively correlated with ACC glutamine levels (r = - 0.55, p = 0.022; r = - 0.58, p = 0.008, respectively). The enhanced glutamate-glutamine metabolism might be due to astroglial activation and the consequent reinforcement of glutamine synthesis in autistic brains. Glutamine synthesis could underly the physiological inhibitory control of dopaminergic D1 receptor signals. Our findings suggest a high neuron excitation-inhibition ratio with astrocytic activation in the etiology of autism.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastorno Autístico / Glutamina Límite: Adult / Humans / Male Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastorno Autístico / Glutamina Límite: Adult / Humans / Male Idioma: En Año: 2023 Tipo del documento: Article